Tags

Type your tag names separated by a space and hit enter

Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
Lung Cancer 2017; 109:89-91LC

Abstract

BACKGROUND

Emergence of the T790M point mutation in exon 20 of epidermal growth factor receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). It remains unclear whether the efficacy of platinum-doublet chemotherapy is impacted by the presence of the T790M mutation. The aim of this study is to evaluate the efficacy of platinum-doublet chemotherapy after initial EGFR-TKI failure according to the EGFR T790M in patients with advanced EGFR-mutation-positive non-small cell lung cancer (NSCLC).

PATIENTS AND METHODS

We retrospectively reviewed 50 patients with advanced NSCLC harboring EGFR mutations who underwent rebiopsy to evaluate their T790M mutation status after development of resistance to first-line EGFR-TKIs (gefitinib, erlotinib, or afatinib) and were subsequently treated with second-line platinum-based chemotherapy.

RESULTS

The median age of patients was 63 years (range, 35-77 years), and 15 (30%) patients were male. Histological examination revealed that all patients had adenocarcinoma, 39 (78%) had stage IV disease, and 11 (22%) patients had postoperative recurrence. Of all, 17 patients (34%) had the T790M mutation by rebiopsy after initial EGFR-TKI failure. The overall response rate (ORR) of platinum-doublet chemotherapy was 24% for both T790M-positive and T790M-negative patients. There was no significant difference in the progression-free survival (PFS) in T790M-positive and T790M-negative patients (median PFS, 6.0 months vs. 5.1 months; 95% confidence interval [CI], 0.1-11.9 vs. 4.4-5.8; hazard ratio [HR], 0.90 [95%CI, 0.49-1.66]; P=0.7210). None of the factors were predictive of platinum-doublet chemotherapy efficacy by the multivariate analysis.

CONCLUSION

There were no differences in clinical outcomes of platinum-based chemotherapy according to the T790M status of NSCLC patients.

Authors+Show Affiliations

Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan. Electronic address: t.yoshida@aichi-cc.jp.Department of Thoracic Surgery, Aichi Cancer Center Hospital, Aichi, Japan.Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.Department of Thoracic Surgery, Aichi Cancer Center Hospital, Aichi, Japan.Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28577956

Citation

Yoshida, Tatsuya, et al. "Clinical Outcomes of Platinum-based Chemotherapy According to T790M Mutation Status in EGFR-positive Non-small Cell Lung Cancer Patients After Initial EGFR-TKI Failure." Lung Cancer (Amsterdam, Netherlands), vol. 109, 2017, pp. 89-91.
Yoshida T, Kuroda H, Oya Y, et al. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure. Lung Cancer. 2017;109:89-91.
Yoshida, T., Kuroda, H., Oya, Y., Shimizu, J., Horio, Y., Sakao, Y., ... Yatabe, Y. (2017). Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure. Lung Cancer (Amsterdam, Netherlands), 109, pp. 89-91. doi:10.1016/j.lungcan.2017.05.001.
Yoshida T, et al. Clinical Outcomes of Platinum-based Chemotherapy According to T790M Mutation Status in EGFR-positive Non-small Cell Lung Cancer Patients After Initial EGFR-TKI Failure. Lung Cancer. 2017;109:89-91. PubMed PMID: 28577956.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure. AU - Yoshida,Tatsuya, AU - Kuroda,Hiroaki, AU - Oya,Yuko, AU - Shimizu,Junichi, AU - Horio,Yoshitsugu, AU - Sakao,Yukinori, AU - Hida,Toyoaki, AU - Yatabe,Yasushi, Y1 - 2017/05/03/ PY - 2017/02/12/received PY - 2017/04/26/revised PY - 2017/05/01/accepted PY - 2017/6/5/entrez PY - 2017/6/5/pubmed PY - 2018/3/10/medline KW - Epidermal growth factor receptor KW - Non-small cell lung cancer (NSCLC) KW - Platinum-doublet chemotherapy KW - T790 M mutation KW - Tyrosine kinase inhibitor SP - 89 EP - 91 JF - Lung cancer (Amsterdam, Netherlands) JO - Lung Cancer VL - 109 N2 - BACKGROUND: Emergence of the T790M point mutation in exon 20 of epidermal growth factor receptor (EGFR) is the most common mechanism of resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). It remains unclear whether the efficacy of platinum-doublet chemotherapy is impacted by the presence of the T790M mutation. The aim of this study is to evaluate the efficacy of platinum-doublet chemotherapy after initial EGFR-TKI failure according to the EGFR T790M in patients with advanced EGFR-mutation-positive non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: We retrospectively reviewed 50 patients with advanced NSCLC harboring EGFR mutations who underwent rebiopsy to evaluate their T790M mutation status after development of resistance to first-line EGFR-TKIs (gefitinib, erlotinib, or afatinib) and were subsequently treated with second-line platinum-based chemotherapy. RESULTS: The median age of patients was 63 years (range, 35-77 years), and 15 (30%) patients were male. Histological examination revealed that all patients had adenocarcinoma, 39 (78%) had stage IV disease, and 11 (22%) patients had postoperative recurrence. Of all, 17 patients (34%) had the T790M mutation by rebiopsy after initial EGFR-TKI failure. The overall response rate (ORR) of platinum-doublet chemotherapy was 24% for both T790M-positive and T790M-negative patients. There was no significant difference in the progression-free survival (PFS) in T790M-positive and T790M-negative patients (median PFS, 6.0 months vs. 5.1 months; 95% confidence interval [CI], 0.1-11.9 vs. 4.4-5.8; hazard ratio [HR], 0.90 [95%CI, 0.49-1.66]; P=0.7210). None of the factors were predictive of platinum-doublet chemotherapy efficacy by the multivariate analysis. CONCLUSION: There were no differences in clinical outcomes of platinum-based chemotherapy according to the T790M status of NSCLC patients. SN - 1872-8332 UR - https://www.unboundmedicine.com/medline/citation/28577956/Clinical_outcomes_of_platinum_based_chemotherapy_according_to_T790M_mutation_status_in_EGFR_positive_non_small_cell_lung_cancer_patients_after_initial_EGFR_TKI_failure_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0169-5002(17)30310-0 DB - PRIME DP - Unbound Medicine ER -